BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 25076292)

  • 1. Progesterone receptor and PTEN expression predict survival in patients with low- and intermediate-grade pancreatic neuroendocrine tumors.
    Estrella JS; Broaddus RR; Mathews A; Milton DR; Yao JC; Wang H; Rashid A
    Arch Pathol Lab Med; 2014 Aug; 138(8):1027-36. PubMed ID: 25076292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of estrogen-induced genes and estrogen receptor β in pancreatic neuroendocrine tumors: implications for targeted therapy.
    Estrella JS; Ma LT; Milton DR; Yao JC; Wang H; Rashid A; Broaddus RR
    Pancreas; 2014 Oct; 43(7):996-1002. PubMed ID: 25058880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of PTEN and mTOR in pancreatic neuroendocrine tumors.
    Han X; Ji Y; Zhao J; Xu X; Lou W
    Tumour Biol; 2013 Oct; 34(5):2871-9. PubMed ID: 23686804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Redefining the Ki-67 Index Stratification for Low-Grade Pancreatic Neuroendocrine Tumors: Improving Its Prognostic Value for Recurrence of Disease.
    Lopez-Aguiar AG; Ethun CG; Postlewait LM; Zhelnin K; Krasinskas A; El-Rayes BF; Russell MC; Sarmiento JM; Kooby DA; Staley CA; Maithel SK; Cardona K
    Ann Surg Oncol; 2018 Jan; 25(1):290-298. PubMed ID: 29079920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical implications and prognostic value of single and combined biomarkers in endometrial carcinoma.
    Li M; Zhao L; Shen D; Li X; Wang J; Wei L
    Chin Med J (Engl); 2014; 127(8):1459-63. PubMed ID: 24762589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemical expression and prognostic value of ER, PR and HER2/neu in pancreatic and small intestinal neuroendocrine tumors.
    Arnason T; Sapp HL; Barnes PJ; Drewniak M; Abdolell M; Rayson D
    Neuroendocrinology; 2011; 93(4):249-58. PubMed ID: 21487213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Morphologic Variants of Pancreatic Neuroendocrine Tumors: Clinicopathologic Analysis and Prognostic Stratification.
    Xue Y; Reid MD; Pehlivanoglu B; Obeng RC; Jiang H; Memis B; Lui SK; Sarmiento J; Kooby D; Maithel SK; El-Rayes B; Basturk O; Adsay V
    Endocr Pathol; 2020 Sep; 31(3):239-253. PubMed ID: 32488621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of Tumor-Associated Macrophages in the Clinical Course of Pancreatic Neuroendocrine Tumors (PanNETs).
    Cai L; Michelakos T; Deshpande V; Arora KS; Yamada T; Ting DT; Taylor MS; Castillo CF; Warshaw AL; Lillemoe KD; Ferrone S; Ferrone CR
    Clin Cancer Res; 2019 Apr; 25(8):2644-2655. PubMed ID: 30670493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Significance of phosphoinositide 3 kinase/AKT pathway alterations in endometrial carcinoma].
    Yang X; Dong Y; Zhang XM; Liang Y; Zhang Y; Meng YT; Wang Y; Wang W; Nong L; Li T; Liao QP
    Zhonghua Bing Li Xue Za Zhi; 2011 Dec; 40(12):799-804. PubMed ID: 22336203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two well-differentiated pancreatic neuroendocrine tumor mouse models.
    Wong C; Tang LH; Davidson C; Vosburgh E; Chen W; Foran DJ; Notterman DA; Levine AJ; Xu EY
    Cell Death Differ; 2020 Jan; 27(1):269-283. PubMed ID: 31160716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive value of preoperative peripheral blood neutrophil/lymphocyte ratio for lymph node metastasis in patients of resectable pancreatic neuroendocrine tumors: a nomogram-based study.
    Tong Z; Liu L; Zheng Y; Jiang W; Zhao P; Fang W; Wang W
    World J Surg Oncol; 2017 May; 15(1):108. PubMed ID: 28558772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DAXX/ATRX and MEN1 genes are strong prognostic markers in pancreatic neuroendocrine tumors.
    Park JK; Paik WH; Lee K; Ryu JK; Lee SH; Kim YT
    Oncotarget; 2017 Jul; 8(30):49796-49806. PubMed ID: 28591701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progesterone receptor negativity is an independent risk factor for relapse in patients with early stage endometrioid endometrial adenocarcinoma.
    Huvila J; Talve L; Carpén O; Edqvist PH; Pontén F; Grénman S; Auranen A
    Gynecol Oncol; 2013 Sep; 130(3):463-9. PubMed ID: 23777659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Coexistence of the loss of heterozygosity at the PTEN locus and HER2 overexpression enhances the Akt activity thus leading to a negative progesterone receptor expression in breast carcinoma.
    Tokunaga E; Oki E; Kimura Y; Yamanaka T; Egashira A; Nishida K; Koga T; Morita M; Kakeji Y; Maehara Y
    Breast Cancer Res Treat; 2007 Mar; 101(3):249-57. PubMed ID: 17006756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Relationships between the molecular biomarkers and the clinicopathologic features and prognosis in endometrial carcinoma].
    Yao YY; Xu WZ; Wang Y; Shen DH; Wang JL; Wei LH
    Beijing Da Xue Xue Bao Yi Xue Ban; 2011 Oct; 43(5):743-8. PubMed ID: 22008688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PTEN/PI3K/AKT protein expression is related to clinicopathological features and prognosis in breast cancer with axillary lymph node metastases.
    Wang LL; Hao S; Zhang S; Guo LJ; Hu CY; Zhang G; Gao B; Zhao JJ; Jiang Y; Tian WG; Wang J; Luo DL
    Hum Pathol; 2017 Mar; 61():49-57. PubMed ID: 27864123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of PTEN expression in neuroendocrine pancreatic tumors.
    Krausch M; Raffel A; Anlauf M; Schott M; Willenberg H; Lehwald N; Hafner D; Cupisti K; Eisenberger CF; Knoefel WT
    Horm Metab Res; 2011 Nov; 43(12):865-71. PubMed ID: 22105477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of PTEN and Increased pAKT Expression Distinguishes Aggressive Low-grade Neuroendocrine Tumors.
    Jayakumar R; Lanjewar S; Axiotis CA
    Ann Clin Lab Sci; 2018 Sep; 48(5):565-572. PubMed ID: 30373859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Grading of well-differentiated pancreatic neuroendocrine tumors is improved by the inclusion of both Ki67 proliferative index and mitotic rate.
    McCall CM; Shi C; Cornish TC; Klimstra DS; Tang LH; Basturk O; Mun LJ; Ellison TA; Wolfgang CL; Choti MA; Schulick RD; Edil BH; Hruban RH
    Am J Surg Pathol; 2013 Nov; 37(11):1671-7. PubMed ID: 24121170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of ARX expression, a novel biomarker for metastatic risk in pancreatic neuroendocrine tumors, in endoscopic ultrasound fine-needle aspiration.
    Hackeng WM; Morsink FHM; Moons LMG; Heaphy CM; Offerhaus GJA; Dreijerink KMA; Brosens LAA
    Diagn Cytopathol; 2020 Apr; 48(4):308-315. PubMed ID: 31846235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.